Knowledge Library

Toxicology Profile of a Novel GLP-1 Receptor Agonist

Glucagon‐like peptide‐1 (GLP-1) receptor agonists have emerged as promising therapeutic options for addressing type‐2 diabetes, obesity, and related conditions. However, because of the continued need for injectable administration, many GLP-1 agonists face compliance challenges. To improve the design and production of GLP-1 receptor biased agonists with enhanced druggability, a novel small molecule, designated SAL0112, was …Read More >

Resource Type: Article, Latest Science, Publication
Resource Topic: Metabolic Diseases, Safety and Early Toxicity, Small Molecules

VIEW

Evaluation of Bispecific Antibodies in NHPs

In recent years, bispecific antibodies (BsAbs) have emerged as a novel strategy in tumor immunotherapy. BsAbs combine two distinct antigen targets within a single antibody molecule, potentially enhancing clinical efficacy and safety. As a result of this dual targeting approach, the clinical therapeutic effects of BsAbs are considered superior to those of monoclonal antibodies. WuXi …Read More >

Resource Type: Presentation
Resource Topic: Antibodies, Oncology, Safety and Early Toxicity

VIEW

Oncolytic Virus Platform

Oncolytic viruses (OVs) are emerging as a promising therapeutic approach for treating cancer. OVs are capable of both tumor-specific cell lysis and immune stimulation and can be optimized for enhanced tumor selectivity.  WuXi AppTec offers a comprehensive platform of OV-related services, including virus engineering and validation, immune profiling and lysis assays, tumor cell selectivity assays, …Read More >

Resource Type: Latest Science, Presentation
Resource Topic: Biochemical Assays, Cell-based Assays, Oncology, Oncolytic Viruses, Safety and Early Toxicity, Tumor Models

VIEW

WuXi AppTec in vitro Neuroscience Services

Neurological disorders, such as neurodegenerative diseases, epilepsy, chronic pain, psychiatric disorders, are one of today’s largest unmet medical needs. However, due to poor disease and target understanding, Neuroscience drug discovery can be very challenging. An open access research platform with dedicated neuroscience specialists and integrated services will be an ideal partner throughout your drug discovery …Read More >

Resource Type: Brochure
Resource Topic: Antibodies, Biochemical Assays, Biomarkers, Cell-based Assays, Cells and Protein Science, Central Nervous System & Pain, Hit Finding, Hit-to-Lead, in vitro biology, Lead Optimization, Phenotypic Assays, Rare Diseases, Safety and Early Toxicity, Small Molecules, Target Identification and Validation

VIEW

Discovery Newsletter November 2022

Resource Type: Latest Science, Newsletter
Resource Topic: CAR-T Cell, Cell-based Assays, Chemical Biology and Proteomics, Discovery Chemistry, DRUG DISCOVERY AND INNOVATION, in vitro biology, Oligonucleotides, Oncolytic Viruses, Safety and Early Toxicity, Small Molecules, Target Identification and Validation, Target-Specific Assays

VIEW

WuXi AppTec Oligonucleotide Biology Platform

We offer a wide range of oligonucleotide services, including: Sequence design Knockdown effect in cell lines and primary cells Splicing analysis Functional assays and assessment of off-target effects Transgenic, HDI and AAV mouse models GalNAc-ASGPR delivery system and customized assays for other delivery systems Stability and protein-protein binding assays Delivery/RISC PK in mouse, rat, and …Read More >

Resource Type: Brochure
Resource Topic: Biochemical Assays, Candidate Selection, Cell-based Assays, Discovery Chemistry, Gene Therapies, Hit-to-Lead, in vivo Pharmacology, Lead Optimization, Liver Diseases, Oligonucleotides, Rare Diseases, Safety and Early Toxicity, Target-Specific Assays

VIEW

Oligonucleotide Drug Discovery

Recent years have seen a huge surge of interest in oligonucleotide therapeutics, fueled by major advances in our understanding of how to make such molecules stable, selective, and efficient as drug modalities. The field is now diverse in terms of therapeutic areas being addressed, biological processes being manipulated and delivery technologies employed. In this webinar, …Read More >

Resource Type: Webinar
Resource Topic: Biochemical Assays, Cell-based Assays, Discovery Chemistry, Hit-to-Lead, in vitro biology, in vivo Pharmacology, Lead Optimization, Oligonucleotides, Safety and Early Toxicity

VIEW

Virology and Viral Vector Platforms

WuXi virology platforms: Immunology, Anti viral, Viral Vector, Oligo-nucleotide, Clinical and Immunology in vitro screening and profiling in vivo efficacy clinical virology Liver-specific viruses | Respiratory viruses | Herpes viruses | Other viruses

Resource Type: Brochure
Resource Topic: Biochemical Assays, Biomarkers, Candidate Selection, CAR-T Cell, Cell-based Assays, Cells and Protein Science, in vivo Pharmacology, in vivo Toxicology, Infectious Diseases, Lead Optimization, Oncolytic Viruses, Phenotypic Assays, Safety and Early Toxicity

VIEW

WuXi AppTec in vitro Safety Pharmacology Profiling

Comprehensive in vitro off-target screening services Safety-related drug failure is a major challenge for the pharmaceutical industry. Approximately 75% of adverse drug reactions (ADRs) are dose-dependent, related to a pharmacological action of the drug, and predictable. The interactions of drugs with off-target proteins have conventionally been viewed as undesirable ‘promiscuity’, responsible for unwanted side effects. …Read More >

Resource Type: Brochure
Resource Topic: Biochemical Assays, Cell-based Assays, Lead Optimization, Safety and Early Toxicity, Target-Specific Assays

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!